Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Medpage Today on MSN2d
NMO Drug Looks Good for IgG4-Related DiseaseWASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...
IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for ...
An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...
AIP is typically accompanied by other organ inflammations such as autoimmune sialadenitis and cholangitis, together ...
ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) The planned clinical study will be executed ...
Amgen (NASDAQ:AMGN) added that a Phase 3 trial called MITIGATE for Uplizna in the treatment of IgG4-related disease met its ...
Ocular autoimmune disease involves the immune system attacking the tissues of the eye. These diseases typically manifest through an autoantibody response targeting the retina, uvea, vitreous, and ...
IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback